Current Report — Form 8-K Filing Table of Contents
Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 21K
2: EX-3.1 Delaware Certificate of Incorporation for Actinium HTML 6K
Pharmaceuticals, Inc.
3: EX-3.2 Bylaws for Actinium Pharmaceuticals, Inc. HTML 65K
4: EX-3.3 Delaware Certificate of Merger HTML 4K
5: EX-3.4 Nevada Articles of Merger HTML 12K
6: EX-99.1 Press Release Dated April 17, 2013 HTML 14K
Registrant’s telephone number, including area code: (212) 300-2131
Cactus Ventures, Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
On April 11, 2013, the change of domicile from the State of Nevada to the State of Delaware and the change of Cactus Ventures, Inc.’s (the “Company”) name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. became effective in accordance with Articles of Merger filed with the State of Nevada and a Certificate of Merger filed with the State of Delaware. Effective April 18, 2013the Company’s new trading symbol is ATNM.
A copy of the press release announcing the change of domicile and name change has been included as an exhibit to this report.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
